Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Antibody
- Disease
- Therapeutic
- Psoriasis
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 243659
Licensor grants a worldwide license under the Licensor Patents and Licensor Know-How in the Field to develop, make, have made, use, sell, offer for sale, have sold and import Licensed Products. Such license shall be co-exclusive with Licensor in the Co-Promotion Territory and exclusive even as to Licensor in the Licensee Territory.
Anti-CD11a means that certain monoclonal antibody, and other constructs with minor modifications thereto resulting from changes to the manufacturing process occurring after the transfer thereof from Licensor to Licensee which is now known as Efalizumab, and which recognizes the CD11a cell adhesion molecule on leucocytes, the full length sequences of the light and heavy chains.
'Initial Indications' means the use of Licensed Product for the treatment of psoriasis and the Organ Transplant Indication. For purposes of this Agreement, psoriasis is a single indication regardless of whether the psoriasis is mild, moderate or severe. Separate Initial Indications will not result based on the severity of the psoriasis or organ transplant rejection, the onset period of organ transplant rejection, or the demographics of the patient class.
Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin.
Anti-CD11a is an investigational, recombinant, humanized monoclonal antibody designed to prevent the activation of T-cells and their migration to sites of inflammation. The first Phase III randomized trial will involve approximately 30 sites throughout the United States and Canada for patients with moderate-to-severe plaque psoriasis. A second Phase III study is planned to begin in the first quarter 2000.
IPSCIO Record ID: 28354
IPSCIO Record ID: 260433
The German Licensor grants to the German Licensee an exclusive license, with the right to grant sublicenses, to the Licensed Technology, other than the Sublicensed Patents and the Sublicensed Know-How, to conduct research and development, make, have made, use, Commercialize, and import the Products in the Field in the Territory.
Licensor grants an exclusive sublicense, with the right to grant further sublicenses, under the rights and licenses granted to Licensor in the Upstream Agreements with respect to the Sublicensed Technology, to research, develop, Commercialize, make, have made, use, offer for sale, sell, and import the Products in the Field in the Territory.
This agreement includes a non-exclusive grant beck from Licensee to Licensor.
GM-CSF means the whole or part and natural variants of the granulocytemacrophage colony stimulating factor (GM-CSF) identified by the SWlSS-PROT entry name CSF2 _ HUMAN and accession number P04141 with the amino acid sequence as defined.
MT203 Product means any pharmaceutical product comprising the IgG1 antibody with the variable domain amino sequence.
The patents are for Antibody neutralizers of human granulocyte macrophage colony stimulating factor; and, Method of identifying binding site domains that retain the capacity of binding to an epitope.
